logo

For the Inventor, By the Inventor

Cassis, France

Jean-Claude Chermann

USPTO Granted Patents = 27



Average Co-Inventor Count = 8.4

ph-index = 5

Forward Citations = 246(Granted Patents)


Location History:

  • Garches, FR (1985)
  • Elancourt, FR (1981 - 2009)
  • Cassis, FR (2007 - 2013)

Company Filing History:

goldMedal13 out of 870 
 
Institut Pasteur
 patents
silverMedal4 out of 5,081 
 
Centre National De La Recherche Scientifique
 patents
bronzeMedal3 out of 3,539 
 
The United States of America, As Represented by the Secretary, Department of Health and Human Services
 patents
4. 2 out of 4 
 
Cabinet Harle & Phelip
 patents
5. 2 out of 123 
 
Institut National De La Recherche Scientifique
 patents
6. 2 out of 338 
 
Agence Nationale De Valorisation De La Recherche (anvar)
 patents
7. 1 out of 1,217 
 
The United States of America As Represented by the Department of Health
 patents
8. 1 out of 46 
 
Agence Nationale De Valorisation De La Recherche
 patents
9. 1 out of 2,202 
 
The United States of America As Represented by the Secretary of
 patents
10. 1 out of 15 
 
Institut Pasteur and Centre National De La Recherche Scientifique
 patents
11. 1 out of 1 
 
Urrma R & D
 patent
12. 1 out of 1 
 
Urrma Biopharma
 patent
13. 5 out of 832,843 
Other
 patents
where one patent can have more than one assignee

Years Active: 1981-2013

Loading Chart...
Loading Chart...
Loading Chart...
27 patents (USPTO):Explore Patents
1. 8507196 - Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1 (2013-08-13),
2. 8329396 - Cloned DNA sequences hybridizable with genomic RNA of lymphadenopathy associated virus (LAV) (2012-12-11),
3. 7626013 - HIV-1 DNA fragments that hybridize to genomic HIV-1DNA (2009-12-01),
4. 7585619 - Method for detecting human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity (2009-09-08),
5. 7306798 - Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same (2007-12-11),
6. 7232654 - DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1) (2007-06-19),
7. 7217508 - Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1) (2007-05-15),
8. 7205102 - Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA (2007-04-17),
9. 7122188 - Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1 (2006-10-17),
10. 6627395 - Methods for the propagation, isolation, identification, and preparation of human immunodeficiency virus type 1 (HIV-1) (2003-09-30),
11. 6600023 - Antibody directed against HIV-1 P25 antigen (2003-07-29),
12. 6440657 - Nucleic acids and peptides of human immunodeficiency virus type (HIV-1) (2002-08-27),
13. 6428952 - Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies (2002-08-06),
14. 6395495 - Methods and kits for detecting antibodies against an HIV variant (2002-05-28),
15. 5843638 - Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1). (1998-12-01),

Title: Jean-Claude Chermann: Pioneering French Inventor

Introduction: Jean-Claude Chermann, a distinguished inventor hailing from Cassis, France, has made significant contributions to the field of innovation with his groundbreaking work.

Latest Patents: Jean-Claude Chermann holds several patents in the areas of biotechnology and pharmaceuticals, showcasing his expertise and creativity in these fields.

Career Highlights: Throughout his illustrious career, Chermann has been recognized for his innovative approach to problem-solving and his ability to translate ideas into tangible inventions that have had a lasting impact on society.

Collaborations: Chermann has collaborated with leading research institutions and pharmaceutical companies, fostering a culture of innovation and knowledge-sharing within the industry.

Conclusion: Jean-Claude Chermann's dedication to pushing the boundaries of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a trailblazing inventor in the global scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…